1034301-08-0

Basic information

• Product Name: 3',5'-di-o-p-chlorobenzoyl-2-deoxy-5-azacytosine
• Synonyms: 3',5'-di-o-p-chlorobenzoyl-2-deoxy-5-azacytosine;4-Amino-1-[3,5-bis-O-(4-chlorobenzoyl)-2-deoxy-beta-D-ribofuranosyl]-1,3,5-triazin-2(1H)-one;3',5'-Bis-O-(4-chlorobenzoyl)-2-deoxy-5-azacytosine;3',5'-Bis-O-(4-chlorobenzoyl)-2-deoxy-5-azacytosine 4-Amino-1-[3,5-bis-O-(4-chlorobenzoyl)-2-deoxy-beta-D-ribofuranosyl]-1,3,5-triazin-2(1H)-one;(2R,3S,5R)-5-(4-Amino-2-oxo-1,3,5-triazin-1(2H)-yl)-2-(((4-chlorobenzoyl)oxy)methyl)tetrahydrofuran-3-yl 4-chlorobenzoate
• CAS NO: 1034301-08-0
• Molecular Formula: C₂₂H₁₈Cl₂N₄O₆
• Molecular Weight: 505.31
• EINECS: 2017-001-1
• Mol File: 1034301-08-0.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 642.6 °C at 760 mmHg
• Flash Point: 342.4 °C
• Appearance: /
• Density: 1.58
• Storage Temp.: Hygroscopic, -20°C Freezer, Under inert atmosphere
• Solubility: Chloroform (Very Slightly, Heated), DMSO (Slightly), Methanol (Slightly, Heated)
• PKA: 3.38±0.20(Predicted)
• CAS DataBase Reference: 3',5'-di-o-p-chlorobenzoyl-2-deoxy-5-azacytosine(CAS DataBase Reference)
• NIST Chemistry Reference: 3',5'-di-o-p-chlorobenzoyl-2-deoxy-5-azacytosine(1034301-08-0)
• EPA Substance Registry System: 3',5'-di-o-p-chlorobenzoyl-2-deoxy-5-azacytosine(1034301-08-0)

Safety Data

• Hazardous Substances Data: 1034301-08-0(Hazardous Substances Data)

Usage

Description

3',5'-di-o-p-chlorobenzoyl-2-deoxy-5-azacytosine, also known as Decitabine USP Related Compound B, is a derivative of β-Decitabine (A796950). It is a compound with a complex chemical structure, characterized by its unique molecular arrangement and properties. 3',5'-di-o-p-chlorobenzoyl-2-deoxy-5-azacytosine has been found to have significant potential in the field of cancer treatment, particularly in inhibiting the growth of certain types of cancer cells.

Uses

Used in Cancer Treatment:
3',5'-di-o-p-chlorobenzoyl-2-deoxy-5-azacytosine is used as an anticancer agent for the treatment of pancreatic endocrine tumor cell lines. It works by inhibiting the growth of these cancer cells, making it a valuable tool in the fight against this specific type of cancer.
Used in Pharmaceutical Research:
In addition to its direct application in cancer treatment, 3',5'-di-o-p-chlorobenzoyl-2-deoxy-5-azacytosine also holds promise in the field of pharmaceutical research. Its unique chemical properties and potential effects on cancer cells make it an interesting compound for further study and development, with the aim of discovering new treatments and therapies for various types of cancer.
Used in Drug Development:
The compound's ability to inhibit the growth of pancreatic endocrine tumor cell lines also makes it a valuable asset in the development of new drugs and therapies. Researchers can use 3',5'-di-o-p-chlorobenzoyl-2-deoxy-5-azacytosine as a starting point or reference compound when designing and testing new drugs, potentially leading to the creation of more effective and targeted cancer treatments.

Upstream product

• 21740-23-8 3,5-O-bis(4-chlorobenzoyl)-2-deoxy-α-D-ribofuranosyl chloride 
• 52523-35-0 2-(trimethylsilylamino)-4-(trimethylsilyloxy)-s-triazine 
• 3601-90-9 5-chloro-2-(((4-chlorobenzoyl)oxy)methyl)tetrahydrofuran-3-yl 4-chlorobenzoate 
• 533-67-5 2-Deoxy-D-ribose 

Downstream Products

• 2353-33-5 5-aza-2'-deoxycytidine 

Relevant articles and documents

Method for synthesizing decitabine intermediate

The invention relates to a method for synthesizing a decitabine intermediate, in particular to a method for synthesizing the decitabine intermediate with a structure shown in a formula 2. According tothe method, the purity of the intermediate can be greatly improved, so that the purification operation of decitabine is reduced, a transition state intermediate compound is successfully separated forthe first time, and the total yield of decitabine is increased by three times.

Preparation method of beta-nucleoside compound

The invention provides a method for preparing beta-nucleoside or analogue thereof, comprising the following steps: 1) enabling nitrogenous base or analogue thereof to generate silylanizing reaction under the existence of trimethylsilyl trifluoromethanesulfonate (TMSOTf), to obtain the nitrogenous base or analogue thereof protected by trimethylsilyl; 2) enabling a reaction liquid to directly perform glycosylation reaction with quintuple cyclose or hexahydric cyclose sealed by a hydroxy protection group, so as to obtain a sealed beta-nucleoside or analogue thereof; 3) performing protection groupremoval reaction, to obtain the beta-nucleoside or analogue thereof. The method disclosed by the invention is simple in operation, energy-saving and environment-friendly, a key intermediate of the beta-nucleoside or analogue thereof is prepared by a one-pot methoid, and the yield of beta configuration substance is remarkably increased, and the preparation method is suitable for industrial application.

PROCESSES FOR PRODUCING DECITABINE

New processes for producing decitabine are provided.